Verilumia 
Novo reports weight loss after switch to Wegovy pill
Novo Nordisk said a real-world study found that 194 people who switched from injectable obesity medicines to its daily Wegovy pill lost an average of 4.1% of their body weight over three months.
Martin Holst Lange News
Recent Verilumia coverage about Martin Holst Lange, EVP of R&D, Chief Scientific Officer and Member of the Management Board at Novo Nordisk A/S.
